{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:18:00Z","timestamp":1784143080865,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic graft-vs-host-disease (cGvHD) is the most relevant long-term complication after allogeneic stem cell transplantation (HSCT) with major impact on non-relapse mortality, but data on intensive care unit (ICU) outcome are missing. In this retrospective, multicenter study we analyzed 174 adult HSCT recipients with cGvHD requiring intensive care treatment. Skin, pulmonary, liver, and intestinal involvement were present in 76.7%, 47.1%, 38.1% and 24.1%, respectively, and a total of 63.2% had severe cGvHD. Main reasons for ICU admission were respiratory failure (69.7%) and sepsis (34.3%). Hospital- and 3-year OS rates were 51.7% and 28.6%, respectively. Global severity of cGvHD did not impact short- and long-term survival. However, patients with severe liver cGvHD or the overlap subtype had a reduced hospital survival, while severe pulmonary cGvHD was associated with worse long-term survival. In multivariate analysis need for invasive ventilation (HR 1.08 (95% CI 1.02\u20131.14)) or hemodialysis (HR 1.73 (95% CI 1.14\u20132.62)) and &lt;1 year since HSCT (HR 1.56 (95% CI 1.03\u20132.39)) were independently associated with a poorer survival. While the global severity of cGvHD does not per se affect patients\u2019 survival after intensive care treatment, pre-existing severe hepatic, intestinal or pulmonary cGvHD is associated with worse outcomes.<\/jats:p>","DOI":"10.1038\/s41409-022-01875-4","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T13:03:14Z","timestamp":1670677394000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients"],"prefix":"10.1038","volume":"58","author":[{"given":"Catherina","family":"Lueck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asterios","family":"Tzalavras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5628-7942","authenticated-orcid":false,"given":"Philipp","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Meedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-3360","authenticated-orcid":false,"given":"Amin T.","family":"Turki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cserna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buchtele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6758-6104","authenticated-orcid":false,"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Liebregts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","volume":"55","author":"JR Passweg","year":"2020","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus. Bone Marrow Transpl. 2020;55:1604\u201313.","journal-title":"Bone Marrow Transpl"},{"key":"1875_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3324\/haematol.2011.055244","volume":"97","author":"JA Perez-Simon","year":"2012","unstructured":"Perez-Simon JA, Afram G, Martino R, Pinana JL, Caballero-Velazquez T, Ringden O, et al. Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica 2012;97:1187\u201395.","journal-title":"Haematologica"},{"key":"1875_CR3","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00134-018-5347-x","volume":"44","author":"C Lueck","year":"2018","unstructured":"Lueck C, Stadler M, Koenecke C, Hoeper MM, Dammann E, Schneider A, et al. Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. Inten. Care Med. 2018;44:1483\u201392.","journal-title":"Inten. Care Med"},{"key":"1875_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00277-018-3320-y","volume":"97","author":"C Orvain","year":"2018","unstructured":"Orvain C, Beloncle F, Hamel JF, Del Galy AS, Thepot S, Mercier M, et al. Allogeneic stem cell transplantation recipients requiring intensive care: time is of the essence. Ann Hematol. 2018;97:1601\u20139.","journal-title":"Ann Hematol"},{"key":"1875_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bmt.2015.269","volume":"51","author":"L Platon","year":"2016","unstructured":"Platon L, Amigues L, Ceballos P, Fegueux N, Daubin D, Besnard N, et al. A reappraisal of ICU and long-term outcome of allogeneic hematopoietic stem cell transplantation patients and reassessment of prognosis factors: results of a 5-year cohort study (2009-2013). Bone Marrow Transpl. 2016;51:256\u201361.","journal-title":"Bone Marrow Transpl"},{"key":"1875_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/bmt.2015.55","volume":"50","author":"E Lengline","year":"2015","unstructured":"Lengline E, Chevret S, Moreau AS, Pene F, Blot F, Bourhis JH, et al. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2015;50:840\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"1875_CR7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","volume":"22","author":"M Grube","year":"2016","unstructured":"Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. Biol Blood Marrow Transpl. 2016;22:1781\u201391.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1875_CR8","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","volume":"118","author":"S Arai","year":"2011","unstructured":"Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242\u20139.","journal-title":"Blood."},{"key":"1875_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3324\/haematol.2011.055186","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica 2012;97:451\u20138.","journal-title":"Haematologica"},{"key":"1875_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1875_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"1875_CR12","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study. JAMA 1993;270:2957\u201363.","journal-title":"JAMA"},{"key":"1875_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"1875_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Inten Care Med. 1996;22:707\u201310.","journal-title":"Inten Care Med"},{"key":"1875_CR15","doi-asserted-by":"crossref","unstructured":"Mayer S, Pastores SM, Riedel E, Maloy M, Jakubowski AA. Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period. Leuk Lymphoma. 2017;58:382\u201390.","DOI":"10.1080\/10428194.2016.1195499"},{"key":"1875_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00277-018-3538-8","volume":"98","author":"AT Turki","year":"2019","unstructured":"Turki AT, Lamm W, Schmitt C, Bayraktar E, Alashkar F, Metzenmacher M, et al. Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. Ann Hematol. 2019;98:491\u2013500.","journal-title":"Ann Hematol"},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2005.03.9073","volume":"24","author":"F Pene","year":"2006","unstructured":"Pene F, Aubron C, Azoulay E, Blot F, Thiery G, Raynard B, et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol. 2006;24:643\u20139.","journal-title":"J Clin Oncol"},{"key":"1875_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/aor.13931","volume":"45","author":"P Wohlfarth","year":"2021","unstructured":"Wohlfarth P, Schellongowski P, Staudinger T, Rabitsch W, Hermann A, Buchtele N, et al. A bi-centric experience of extracorporeal carbon dioxide removal (ECCO2 R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation. Artif Organs. 2021;45:903\u201310.","journal-title":"Artif Organs"},{"key":"1875_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jcrc.2015.06.020","volume":"30","author":"D Mokart","year":"2015","unstructured":"Mokart D, Granata A, Crocchiolo R, Sannini A, Chow-Chine L, Brun JP, et al. Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. J Crit Care. 2015;30:1107\u201313.","journal-title":"J Crit Care"},{"key":"1875_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000440937","volume":"135","author":"SC Lindgaard","year":"2016","unstructured":"Lindgaard SC, Nielsen J, Lindmark A, Sengelov H. Prognosis of Allogeneic Haematopoietic Stem Cell Recipients Admitted to the Intensive Care Unit: A Retrospective, Single-Centre Study. Acta Haematol. 2016;135:72\u20138.","journal-title":"Acta Haematol"},{"key":"1875_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.CCM.0000256846.27192.7A","volume":"35","author":"L Lecuyer","year":"2007","unstructured":"Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay E. The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med. 2007;35:808\u201314.","journal-title":"Crit Care Med"},{"key":"1875_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56322-0","volume":"9","author":"CS Michel","year":"2019","unstructured":"Michel CS, Teschner D, Schmidtmann I, Theobald M, Hauptrock B, Wagner-Drouet EM, et al. Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. Sci Rep. 2019;9:19911.","journal-title":"Sci Rep."},{"key":"1875_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41409-018-0277-3","volume":"54","author":"PLJ van der Heiden","year":"2019","unstructured":"van der Heiden PLJ, Arbous MS, van Beers EJ, van den Bergh WM, le Cessie S, Demandt AMP, et al. Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation. Bone Marrow Transpl. 2019;54:418\u201324.","journal-title":"Bone Marrow Transpl"},{"key":"1875_CR24","doi-asserted-by":"publisher","first-page":"e500","DOI":"10.1097\/CCM.0000000000002293","volume":"45","author":"P Wohlfarth","year":"2017","unstructured":"Wohlfarth P, Beutel G, Lebiedz P, Stemmler HJ, Staudinger T, Schmidt M, et al. Characteristics and Outcome of Patients After Allogeneic Hematopoietic Stem Cell Transplantation Treated With Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome. Crit Care Med. 2017;45:e500\u2013e7.","journal-title":"Crit Care Med"},{"key":"1875_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793\u2013800.","journal-title":"Crit Care Med"},{"key":"1875_CR26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00277-018-3312-y","volume":"97","author":"MG Kiehl","year":"2018","unstructured":"Kiehl MG, Beutel G, Boll B, Buchheidt D, Forkert R, Fuhrmann V, et al. Consensus statement for cancer patients requiring intensive care support. Ann Hematol. 2018;97:1271\u201382.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01875-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01875-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T19:38:27Z","timestamp":1679859507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01875-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01875-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ATT received honoraria from CSL Behring, MSD and Maat Pharma. CL has received travel subsidies from Jazz Pharmaceuticals and Neovii. DW received honoraria from Novartis, Mallinckrodt, Gilead, Pfizer, Takeda, and Incyte and research support from Novartis. PS received honoraria from Astro-Pharma, Biotest, Jazz Pharmaceuticals, Kite\/Gilead, Novartis, Orion, Pfizer and Shire and research support by the European Commission (Horizon 2020 Fast Track Innovation Grant). The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}